Tranexamic acid (TA), a synthetic derivative of the amino acid lysine, is an antifibrinolytic, procoagulant agent that the Food and Drug Administration approves for the treatment of cyclic heavy menstrual bleeding and prevention of bleeding in patients with hemophilia undergoing tooth extractions. 1 Oral TA has been used off-label in dermatology in the treatment of melasma and other hyperpigmentation disorders. 2 In a recent study, oral TA has been reviewed thoroughly in treating melasma, and its effectiveness has been demonstrated. 2 Their role in treating other hyperpigmentation disorders has also been tried in several studies. The present review discusses the emerging role of oral TA in the treatment of hyperpigmentation disorders other than melasma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.